Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.
Top Cited Papers
- 1 August 2008
- journal article
- review article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 86 (8), 485-498
- https://doi.org/10.1139/y08-059
Abstract
Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence.The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.Keywords
This publication has 101 references indexed in Scilit:
- Endothelins are vascular-derived axonal guidance cues for developing sympathetic neuronsNature, 2008
- The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?British Journal of Pharmacology, 2008
- Clinical trials of endothelin antagonists in heart failure: publication is good for the public healthHeart, 2007
- Endothelin‐1 inhibits adipogenesis: Role of phosphorylation of Akt and ERK1/2FEBS Letters, 2006
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals Of The Rheumatic Diseases, 2006
- Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: Evidence for endothelin release by pancreatic islet β-cellsBiochemical and Biophysical Research Communications, 2005
- Endothelin Receptor AntagonistsJournal of Cardiovascular Pharmacology, 2005
- Endothelin antagonists in renal diseaseKidney International, 2000
- Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus.Annals Of The Rheumatic Diseases, 1995
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980